Ian S Dunn

Summary

Publications

  1. ncbi RNA templating of molecular assembly and covalent modification patterning in early molecular evolution and modern biosystems
    Ian S Dunn
    CytoCure LLC, 100 Cummings Center, Beverly, MA 01915, USA
    J Theor Biol 284:32-41. 2011
  2. ncbi Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells
    Timothy J Haggerty
    CytoCure LLC, 100 Cummings Center, Suite 430C, Beverly, MA 01915, USA
    Cancer Immunol Immunother 60:133-44. 2011

Research Grants

  1. Transcription Regulation of Melanoma Antigen Expression
    Ian Dunn; Fiscal Year: 2002
  2. GFP-Reporter Constructs for Tumor Antigen Regulation
    Ian Dunn; Fiscal Year: 2002

Collaborators

  • Timothy J Haggerty
  • Lenora B Rose
  • Estelle E Newton
  • James L Riley
  • James T Kurnick
  • Sunil Martin

Detail Information

Publications2

  1. ncbi RNA templating of molecular assembly and covalent modification patterning in early molecular evolution and modern biosystems
    Ian S Dunn
    CytoCure LLC, 100 Cummings Center, Beverly, MA 01915, USA
    J Theor Biol 284:32-41. 2011
    ..Awareness of these formal possibilities may also assist in the current search for functions of extensive non-coding RNAs in complex organisms, or for efforts towards artificial rendering of DRT systems...
  2. ncbi Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells
    Timothy J Haggerty
    CytoCure LLC, 100 Cummings Center, Suite 430C, Beverly, MA 01915, USA
    Cancer Immunol Immunother 60:133-44. 2011
    ....

Research Grants2

  1. Transcription Regulation of Melanoma Antigen Expression
    Ian Dunn; Fiscal Year: 2002
    ..The results of this Phase I project will allow us to devise strategies for enhancement of Melan-A/MART-1 expression to overcome "antigen-silencing." ..
  2. GFP-Reporter Constructs for Tumor Antigen Regulation
    Ian Dunn; Fiscal Year: 2002
    ..Such novel drugs will induce the maintenance and/or up-regulation of tumor antigen expression necessary to achieve efficacy in cellular immune-based tumor therapies. ..